All In Biotech

NDA 022044 · Msd Sub Merck

Janumet

Metformin Hydrochloride, Sitagliptin Phosphate · Oral

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Mar 30, 2007

Approved uses

8

Original approval plus efficacy supplements

Registered trials

2,828

753 Phase 3, 150 recruiting

FAERS reports

19,518

13,277 serious, 2,052 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ] . Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...

What it is approved for

From the label in effect Aug 11, 2026.

JANUMET ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use JANUMET should not be used in patients with type 1 diabetes mellitus. JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET [see Warnings and Precautions (5.2) ]. JANUMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: JANUMET should not be used in patients with type 1 diabetes. ( 1 ) JANUMET has not been studied in patients with a history of pancreatitis. ( 1 , 5.2 )

Mechanism: JANUMET JANUMET combines two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin HCl, a member of the biguanide class. Sitagliptin Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • JANUMET · METFORMIN HYDROCHLORIDE 500MG; SITAGLIPTIN PHOSPHATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
  • JANUMET · METFORMIN HYDROCHLORIDE 1GM; SITAGLIPTIN PHOSPHATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Metformin" as an intervention, any sponsor and status, largest first.

All 2,828 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased1,318
  • diarrhoea1,214
  • nausea1,004
  • drug ineffective886
  • acute kidney injury823
  • fatigue821
  • vomiting706
  • weight decreased671
  • dyspnoea581
  • pancreatic carcinoma575
  • pancreatitis575
  • dizziness573

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200739
2008131
2009254
2010384
2011537
2012839
20131,225
20141,686
20152,188
20161,897
20171,497
20181,634
20191,481
20201,378
20211,149
2022909
2023801
2024664
2025505
2026320

Recalls

1 FDA enforcement reports for this application.

  • Mar 31, 2022 · Class II · Terminated

    Presence of foreign substance: Presence of stainless steel particulates in tablets.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Janumet (Sitagliptin Phos/Metformin HCl)

2024 spending

$709M

Beneficiaries

159,321

743,903 claims

Per beneficiary

$4,451

$8.97 per unit

View as table
YearSpending
2020$791,886,114
2021$814,640,687
2022$815,605,370
2023$798,865,849
2024$709,178,278

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,495 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.